Filter News
Area of Research
- (-) Isotopes (5)
- (-) Neutron Science (10)
- Advanced Manufacturing (1)
- Biology and Environment (9)
- Building Technologies (1)
- Clean Energy (9)
- Computational Engineering (2)
- Computer Science (4)
- Fusion and Fission (1)
- Materials (3)
- Materials for Computing (3)
- Mathematics (1)
- National Security (2)
- Quantum information Science (1)
- Supercomputing (7)
News Type
Media Contacts
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
An Oak Ridge National Laboratory researcher has invented a version of an isotope-separating device that can withstand extreme environments, including radiation and chemical solvents.
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
Researchers from NASA’s Jet Propulsion Laboratory and Oak Ridge National Laboratory successfully created amorphous ice, similar to ice in interstellar space and on icy worlds in our solar system. They documented that its disordered atomic behavior is unlike any ice on Earth.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Using complementary computing calculations and neutron scattering techniques, researchers from the Department of Energy’s Oak Ridge and Lawrence Berkeley national laboratories and the University of California, Berkeley, discovered the existence of an elusive type of spin dynamics in a quantum mechanical system.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.